home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences

Search

 
  Drug Discovery and Clinical Evaluation in the 21st Century  
  June 21, 2001

Others

 
     
  UT M. D. Anderson Cancer Center, JW Marriott Hotel, 5150 Westheimer, Houston, Texas
January 16-18, 2002


WEDNESDAY A.M. - JANUARY 16, 2002

Welcome
John Mendelsohn, M.D.
President
UT M. D. Anderson Cancer Center

Keynote Speaker

Drug Discovery, Development and Evaluation from NCI's Perspective
Richard Klausner, M.D.
National Cancer Institute
Bethesda, Maryland

SESSION I: IDENTIFICATION AND PRIORITIZATION OF NOVEL DRUG TARGETS
Session Co-chairs: Gabriel Lopez-Berestein, M.D. and William K. Plunkett Jr., M.D.

Apoptosis
Stanley Korsmeyer, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts

Cell Cycle
William Kaelin, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts

Kinases
Carlos Arteaga, M.D.
Vanderbilt University School of Medicine
Nashville, Tennessee

Signal Transduction Targets I
Frank McCormick, M.D.
University of San Francisco Cancer Center &
Cancer Research Institute
San Francisco, California

Signal Transduction II
Philip Needleman, Ph.D.
Monsanto Corporation
St. Louis, Missouri

Angiogenesis/Metastasis
Judah Folkman, M.D.
Harvard Medical School
Boston, Massachusetts

Genomics/Proteomics
Robert Tepper, M.D.
Millennium Pharmaceuticals
Cambridge, Massachusetts

Discussion
Kirt Matheson
Aventis

Mark Sliwkowski
Genentech, Inc.
South San Francisco, California

Lunch

WEDNESDAY P.M. - JANUARY 16, 2002

SESSION II: METHODS FOR PRECLINICAL EVALUATION AND PRIORITIZATION OF NOVEL DRUGS
Session Co-chairs: Francis Ali-Osman, DSc and Stanley Hamilton, M.D.

High Through Put Screening
Raymond Budde, Ph.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Cell Lines
John Weinstein, M.D.
National Cancer Institute
Bethesda, Maryland

Clonogenic Assays
John Fruehauff, M.D., Ph.D.
Oncotech, Inc.
Irvine, California

Animal Models
Beverly Teicher, Ph.D.
Lilly Research Laboratories
Indianapolis, Indiana

Academic Perspective
Daniel Von Hoff, M.D.
Arizona Cancer Center
Tucson, Arizona

Industrial Perspective
Ivan Horak, M.D.
Pharmacia & Upjohn
Peapack, New Jersey

FDA Perspective
Karen Weiss, M.D.
Food and Drug Administration
Rockville, Maryland

Discussion
Praveen Tyle, Ph.D.
Pharmacia & Upjohn
Kalamazoo, Michigan

Louise Perkins, Ph.D.
Bayer Corp.
West Haven, CT

Reception

THURSDAY A.M. - JANUARY 17, 2002

Keynote Speaker

Regulatory Processes in the Development and Evaluation of New Cancer Drugs
Janet Woodcock, M.D.
Food and Drug Administration
Rockville, Maryland

SESSION III: NOVEL CLINICAL TRIAL DESIGN AND IMPLEMENTATION
Session Co-chairs: Gabriel Hortobagyi, M.D. and Elihu Estey, M.D.

Trial Design I
Richard Gelber, Ph.D.
Dana-Farber Cancer Institute
Boston, Massachusetts

Trial Design II
Donald Berry, Ph.D.
UT M. D. Anderson Cancer Center
Houston, Texas

FDA
Richard Pazdur, M.D.
Food and Drug Administration
Rockville, Maryland

EORTC
Martine Piccart-Gebhart, M.D., Ph.D.
Jules Bordet Institute
Brussels, Belgium

US Trials
Richard Schilsky, M.D.
University of Chicago
Chicago, Illinois

Industry
David Parkinson
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey

NCI
Robert Wittes, M.D.
National Cancer Institute
Bethesda, Maryland

Discussion
Steven Averbush, M.D.
Astra-Zeneca
Wilmington, Delaware

Perry Nisen
Abbott Laboratories
Abbott Park, IL

Lunch

THURSDAY P.M. - JANUARY 17, 2002

SESSION IV: CLINICAL TRIALS: ENDPOINTS AND PARTICIPANTS
Session Co-chairs: Eugenie Kleinerman, M.D. and Michael Keating, M.D.

Molecular Endpoints
Gordon B. Mills, M.D., Ph.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Pharmacogenomics
Robert Kramer, M.D.
Bristol-Myers Squibb
Princeton, New Jersey

Diagnostic Imaging
Donald Podoloff, M.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Supportive Care
William Sheridan, MBBS
Amgen, Inc.
Thousand Oaks, California

Pediatric Trials
Gregory Reaman, M.D.
Children's National Medical Center
Washington, DC

Adult Phase I-II Trials
Hagop M. Kantarjian, M.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Geriatric Trials
Hyman Muss, M.D.
University of Vermont
Burlington, Vermont

Women & Minorities
Edith Mitchell, M.D.
Thomas Jefferson University
Philadelphia, Pennsylvania

Discussion
Maryellen Ryback, M.D.
Janssen Research Foundation
Titusville, New Jersey

David Luke, Pharm.D
Pfizer Global Research and Development
Groton, CT

FRIDAY A.M. - JANUARY 18, 2002

Keynote Speaker

Drug Discovery, Development and Evaluation in the 21st Century From Industry’s Perspective
Steve Carter, M.D.
Consultant
New York, New York

SESSION V: THE IMMEDIATE FUTURE OF MOLECULAR THERAPEUTICS
Session Co-chairs: Waun Ki Hong, M.D. and Raphael E. Pollock, M.D., Ph.D.

Tyrosine Kinase Inhibitors
Moshe Talpaz, M.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Monoclonal Antibodies
Louis Weiner, M.D.
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Farnesyl Transferase Inhibitors
Allen Oliff, M.D.
Dupont Pharmaceuticals
Wilmington, Delaware

Angiogenesis Inhibitors
Roy Herbst, M.D., Ph.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Retinoids
Richard Heyman, Ph.D.
X-Ceptor Therapeutics
San Diego, California

Anti-Sense
Ana Tari, Ph.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Gene Therapy
Jack A. Roth, M.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Radiation Response Modifiers
Norman Coleman, M.D.
National Cancer Institute
Bethesda, Maryland

PRESENTATION OF THE HEATH MEMORIAL AWARD

Vaccines
Steven Rosenberg, M.D., Ph.D.
National Cancer Institute
Bethesda, Maryland
 
 
Organized by: UT M. D. Anderson Cancer Center
Invited Speakers: Carlos Arteaga, M.D.
Vanderbilt University School of Medicine
Nashville, Tennessee

Steven Averbush, M.D.
Astra-Zeneca
Wilmington, Delaware

Donald Berry, Ph.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Raymond Budde, Ph.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Steve Carter, M.D.
Consultant
New York, New York

Norman Coleman, M.D.
National Cancer Institute
Bethesda, Maryland

Judah Folkman, M.D.
Harvard Medical School
Boston, Massachusetts

John Fruehauff, M.D., Ph.D.
Oncotech, Inc.
Irvine, California

Richard Gelber, Ph.D.
Dana-Farber Cancer Institute
Boston, Massachusetts

Roy Herbst, M.D., Ph.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Richard Heyman, Ph.D.
X-Ceptor Therapeutics
San Diego, California

Ivan Horak, M.D.
Pharmacia & Upjohn
Peapack, New Jersey

William Kaelin, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts

Hagop M. Kantarjian, M.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Richard Klausner, M.D.
National Cancer Institute
Bethesda, Maryland

Stanley Korsmeyer, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts

Robert Kramer, M.D.
Bristol-Myers Squibb
Princeton, New Jersey

Gabriel Lopez-Berestein, M.D.
UT M. D. Anderson Cancer Center
Houston, Texas

David Luke, Pharm.D
Pfizer Global Research and Development
Groton, CT

Kirt Matheson
Aventis

Frank McCormick, M.D.
University of San Francisco Cancer Center &
Cancer Research Institute

John Mendelsohn, M.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Gordon B. Mills, M.D., Ph.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Edith Mitchell, M.D.
Thomas Jefferson University
Philadelphia, Pennsylvania

Hyman Muss, M.D.
University of Vermont
Burlington, Vermont

Philip Needleman, Ph.D.
Monsanto Corporation
St. Louis, Missouri

Perry Nisen
Abbott Laboratories
Abbott Park, IL

Allen Oliff, M.D.
Dupont Pharmaceuticals
Wilmington, Delaware

David Parkinson
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey

Richard Pazdur, M.D.
Food and Drug Administration
Rockville, Maryland

Louise Perkins, Ph.D.
Bayer Corp.
West Haven, CT

Martine Piccart-Gebhart, M.D., Ph.D.
Jules Bordet Institute
Brussels, Belgium

William K. Plunkett Jr., M.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Donald Podoloff, M.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Gregory Reaman, M.D.
Children’s National Medical Center
Washington, DC

Steven Rosenberg, M.D., Ph.D.
National Cancer Institute
Bethesda, Maryland

Jack A. Roth, M.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Maryellen Ryback, M.D.
Janssen Research Foundation
Titusville, New Jersey

Richard Schilsky, M.D.
University of Chicago
Chicago, Illinois

William Sheridan, MBBS
Amgen, Inc.
Thousand Oaks, California

Mark Sliwkowski
Genentech, Inc.
South San Francisco, California

Moshe Talpaz, M.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Ana Tari, Ph.D.
UT M. D. Anderson Cancer Center
Houston, Texas

Beverly Teicher, Ph.D.
Lilly Research Laboratories
Indianapolis, Indiana

Robert Tepper, M.D.
Millennium Pharmaceuticals
Cambridge, Massachusetts

Praveen Tyle, Ph.D.
Pharmacia & Upjohn
Kalamazoo, Michigan

Daniel Von Hoff, M.D.
Arizona Cancer Center
Tucson, Arizona

Louis Weiner, M.D.
Fox Chase Cancer Center
Philadelphia, Pennsylvania

John Weinstein, M.D.
National Cancer Institute
Bethesda, Maryland

Karen Weiss, M.D.
Food and Drug Administration
Rockville, Maryland

Robert Wittes, M.D.
National Cancer Institute
Bethesda, Maryland

Janet Woodcock, M.D.
Food and Drug Administration
Rockville, Maryland
 
Deadline for Abstracts: N/A
 
Registration: On-site registration opens at 7:00 a.m. on Wesnesday, January 16, 2002, followed by the opening session at 8:00 a.m., and the conference will adjourn at 12:00 noon on Friday, January 18, 2002. Advance registration is encouraged as space and materials are limited. The deadline for advance registration is January 4, 2002. To pre-register, please go to the conference website and complete the on-line registration form. MasterCard, VISA, and American Express are accepted for on-line or Fax: 713-794-1724. If you are paying by check(payable through U.S. banks only) or money order to:
43rd Annual Clinical Conference, conference Services-HMB 131, UT M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009.

Registration Fee Schedule:
The full conference registration fee includes the tuition, two lunches, breaks, and receptions. The student registration fee includes all of the above excluding lunches. Students wishing to participate in lunches, must pay an additional fee of $35.00.

Postmarked: by 1/4/02 after 1/4/02
Full conference registration fee $375 $400
M. D. Anderson $250 $300
Associates Members
Student registration fee $100 $125
Student lunch fee $35 $40

Students: A reduced registration fee has been established for full-time students and physicians in training (interns, residents, and fellows). All students claiming this reduced fee are required to submit a letter of introduction from the chairperson of their department with their registration form.
E-mail: meetings@mdaisd1.tmc.edu
 
  Posted by:   Pam Hamre  
Host: conf100.mdacc.tmc.edu
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2001 HUM-MOLGEN. All rights reserved. Liability and Copyright.